Acanthosis nigricans
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Ndizofala mwa anthu onenepa kwambiri.
References
Acanthosis nigricans ndi chiwonetsero chakhungu cha vuto lomwe lili pansi. Nthawi zambiri amawonekera pakhungu ngati m'khosi, m'khwapa, ndi groin, zowoneka ngati zigamba zakuda zowoneka bwino m'mbali mwake. Matendawa nthawi zambiri amakhudzana ndi matenda a shuga komanso kukana insulini, koma nthawi zina, amatha kuloza khansa mkati mwa thupi. Zitha kuwonekeranso chifukwa cha vuto la mahomoni kapena kumwa mankhwala enaake monga ma steroids ndi mapiritsi oletsa kubereka.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) ndizovuta zapakhungu zomwe zimagwirizanitsidwa ndi zovuta zosiyanasiyana zaumoyo monga kukana insulini, shuga, kunenepa kwambiri, khansa zina, mavuto a mahomoni, komanso momwe angagwiritsire ntchito mankhwala. Kuchiza AN kumayang'ana kwambiri kuthana ndi mavuto omwe amayambitsa thanzi. Poyamba, madokotala amafufuza zizindikiro za insulin resistance syndrome, zomwe zimaphatikizapo kunenepa kwambiri, cholesterol yambiri, kuthamanga kwa magazi, ndi matenda a shuga a mtundu wachiwiri. Madokotala nthawi zambiri amalembera topical retinoids ngati chithandizo choyamba, chomwe chingathandize pakukhuthala kwa khungu. Komabe, sangathetseretu mdima wa khungu. Njira zina zothandizira (salicylic acid, podophyllin, urea, calcipotriol) zimafunikanso kugwiritsa ntchito pafupipafupi.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Zifukwa
Amapezeka mwa anthu ochepera zaka 40, amatha kutengera chibadwa ndipo amalumikizidwa ndi kunenepa kwambiri kapena matenda am'mimba, monga hypothyroidism, acromegaly, polycystic ovary matenda, matenda a shuga osamva insulin kapena matenda a Cushing.
○ Chithandizo ― OTC Mankhwala
#40% urea cream